New findings that RAD52 is essential for cell viability in BRCA1-, PALB2-, BRCA2- and RAD51 paralog-deficient cells but not in normal cells have suggested that RAD52 may represent an attractive therapeutic target for killing breast cancer and ovarian cancer cells [11]. This evidence concerns the gene RAD52 and breast cancer.